{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HMA&page=2", "query": { "intervention": "HMA", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HMA&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T05:57:12.499Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06511882", "title": "Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2024-11-07", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06511882" }, { "nct_id": "NCT04467489", "title": "Biomarkers of CASH", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cerebral Cavernous Malformation", "Cavernous Angioma", "Hemorrhagic Microangiopathy" ], "interventions": [ { "name": "observational", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1040, "start_date": "2020-05-22", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 4, "location_summary": "Phoenix, Arizona • San Francisco, California • Chicago, Illinois + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04467489" }, { "nct_id": "NCT04229979", "title": "Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Galinpepimut-S", "type": "BIOLOGICAL" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Observation", "type": "OTHER" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "Montanide", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Sellas Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2021-02-08", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Whittier, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04229979" }, { "nct_id": "NCT07148947", "title": "Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2026-03-02", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148947" }, { "nct_id": "NCT01442922", "title": "Intervertebral Disc Augmentation With Minimally Invasive Surgical Procedure", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Degenerative Disc Disease" ], "interventions": [ { "name": "completion of the (VAS) for level of back pain", "type": "OTHER" }, { "name": "completion of the (OLBPQ) for assessment of function", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "44 Years", "sex": "ALL", "summary": "18 Years to 44 Years" }, "enrollment_count": 1, "start_date": "2011-03", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2013-01-17", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01442922" }, { "nct_id": "NCT01912274", "title": "Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Pracinostat", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 50, "start_date": "2013-12-24", "completion_date": "2016-11-08", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 17, "location_summary": "Duarte, California • Los Angeles, California • Pleasant Hill, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pleasant Hill", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01912274" }, { "nct_id": "NCT05428969", "title": "A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndromes", "Relapsed/Refractory AML" ], "interventions": [ { "name": "Bexmarilimab", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Faron Pharmaceuticals Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 181, "start_date": "2022-06-02", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 4, "location_summary": "Duarte, California • New Haven, Connecticut • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05428969" }, { "nct_id": "NCT01993641", "title": "Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "MDS" ], "interventions": [ { "name": "pracinostat", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2013-12", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 21, "location_summary": "Mobile, Alabama • Duarte, California • Los Angeles, California + 17 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01993641" }, { "nct_id": "NCT06552416", "title": "Safety of MT-401-OTS in Patients With Relapsed AML or MDS", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia, in Relapse", "MDS" ], "interventions": [ { "name": "MT-401-OTS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marker Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 40, "start_date": "2025-06-16", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 3, "location_summary": "Duarte, California • Tampa, Florida • Kansas City, Kansas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06552416" }, { "nct_id": "NCT02469415", "title": "Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "5-azacitidine", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2015-09-30", "completion_date": "2017-06-03", "has_results": true, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-09-25T05:57:12.499Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469415" } ] }